Sinovac Biotech (SVA) said Sunday it has been notified by Nasdaq that it has failed to comply with a listing rule requiring the timely filing of a Form 6-K containing an interim balance sheet and income statement at the end of Q2 2025.
The company said it is evaluating the notification and intends to present its plan at a scheduled hearing on Jan. 8 with the objective of maintaining its Nasdaq listing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.